Background {#Sec1}
==========

Thirteen human polyomaviruses (HPyVs) have been identified to date. Up to 2007, only two HPyVs had been introduced by cell culture: BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV), coincidentally in 1971 \[[@CR1], [@CR2]\]. Since then, eleven HPyVs have been discovered by modern molecular techniques \[[@CR3]--[@CR14]\]. All HPyVs have high seroprevalences in human populations ranging from 40 to 90% in adults \[[@CR15]--[@CR26]\]. Typically, the primary infections occur asymptomatically during childhood and are followed by lifelong DNA persistence. In immunocompromised hosts some of these viruses give rise to severe disorders such as nephropathy, progressive multifocal leukoencephalopathy, Merkel cell carcinoma or trichodysplasia spinulosa \[[@CR5], [@CR7], [@CR27], [@CR28]\]. The other HPyVs, i.e. KIPyV, WUPyV, HPyV6, HPyV7, HPyV9, HPyV10 (MWPyV), Saint Louis polyomavirus (STLPyV), HPyV12 and New Jersey polyomavirus (NJPyV)-2013, have up to date not been definitively associated with specific diseases.

On the other hand, evidence suggests that tonsils are permissive for JCPyV and BKPyV, indicating that this tissue might play a role in the viral persistence \[[@CR29]--[@CR34]\]. KIPyV and WUPyV, the first two novel polyomaviruses discovered in the respiratory secretions of children with acute respiratory symptoms, \[[@CR3], [@CR4]\] might also remain in lymphoid tissue as suggested by detection of the corresponding sequences in tonsils \[[@CR29], [@CR35], [@CR36]\]. We have reported the occurrence of DNA of MCPyV and TSPyV in tonsillar tissue, suggesting persistence in lymphoid tissue or mucosa \[[@CR36], [@CR37]\]. MCPyV is a common skin commensal and causes about 80% of cases of Merkel cell carcinoma (MCC) \[[@CR5], [@CR38]--[@CR40]\]. TSPyV induces the rare skin disease trichodysplasia spinulosa (TS) in immunocompromised patients \[[@CR7]\]. HPyV6 and HPyV7 identified in skin and eyebrow hairs, have in one study been isolated from malignant and non-malignant tonsils \[[@CR6], [@CR38], [@CR40]--[@CR42]\]. HPyV9 was identified in 2010 in the serum of a kidney transplant patient under immunosuppressive treatment \[[@CR8]\]. Its DNA was found in serum, PBMCs and skin \[[@CR38], [@CR43], [@CR44]\]. HPyV10 was originally detected in stool, while the isolate MWPyV was first encountered in the skin of a patient with the "warts, hypogammaglobulinaemia, infections and myelokathexis" (WHIM) syndrome. MXPyV, another HPyV10 isolate, was found in stool and in respiratory samples, \[[@CR9], [@CR10], [@CR45]\] while STLPyV DNA was amplified in stool and urine \[[@CR13]\]. A STLPyV variant sharing 92% genome identity with the originally described MA138 and WD972 strains, was amplified from skin warts of a patient suffering from WHIM syndrome \[[@CR46]\]. HPyV12 was found in organs of the digestive tract, particularly in the liver but also in colon, rectum and stool \[[@CR47]\]. NJPyV DNA sequences and virions were originally detected in a muscle biopsy of a pancreatic transplant recipient with viral sequences also found in endothelial cells in muscle and skin \[[@CR48]\].

To demonstrate clinical correlates and disease associations for HPyVs, as with most other viruses, the diagnostic cornerstones are nucleic acid detection and serodiagnosis. To this end, we have developed and validated several PCR protocols \[[@CR37], [@CR49]--[@CR51]\]. The Luminex technology offers a novel platform for sensitive and specific, high-throughput multiplex DNA detection. An assay has earlier been set up for the detection of 10 HPyVs \[[@CR52], [@CR53]\]. We here describe the further development of this multiplex nucleic acid assay for the detection of all 13 HPyVs currently known, in a clinically applicable format. By combining multiplex PCR amplification with bead based hybridization and flow cytometric analysis, the resulting Luminex-based multiplex assay can simultaneously identify all the 13 HPyVs in a single reaction.

Herein, the multiplex assay is evaluated for specificity, sensitivity and reproducibility. Furthermore, we aimed to determine to what extent the lymphoid system plays a role in HPyV infection and persistence by exploring the frequencies of occurrence of these viral genomes in tonsillar biopsies from children and adults with tonsillar disease.

Methods {#Sec2}
=======

Clinical specimens {#Sec3}
------------------

The clinical material comprised tonsillar tissue from 78 subjects: 31 children and 47 adults (Fig. [1](#Fig1){ref-type="fig"}). The pediatric donors ranged in age from 2 to 15 years (average, 6.6), and the adults from 16 to 69 (average, 30.3). Of the specimens, 31 were from males and 47 from females (Fig. [1](#Fig1){ref-type="fig"}). The tonsillectomies and tonsillotomies were performed in most cases due to chronic tonsillitis or tonsillar hypertrophy (Fig. [1](#Fig1){ref-type="fig"}). All tissues were collected and used in accordance with the ethical rules of the Ethics Committee of the Hospital District of Helsinki and Uusimaa. All tonsil tissues were freshly obtained directly after surgical resection at the operation theatre. The tonsils were cut with disposable scalpels and cell suspensions were prepared by mechanical homogenisation with a syringe plunge, followed by a wash with PBS and filtration through a 70 μm mesh (Corning Life Sciences). The cells were resuspended into final volume of 100 μL PBS.Fig. 1Tonsillar samples from children and adults; clinical indications

Nucleic acid extraction {#Sec4}
-----------------------

Whole DNA was extracted from cell suspension by the KingFisher Duo DNA Extraction Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Standard precautions to avoid contamination were taken. The extracted DNA was stored at −20 °C.

Primer pairs and probes {#Sec5}
-----------------------

Primer pairs and probes for 13 HPyVs (BKPyV, JCPyV, KIPyV, WUPyV, MCPyV, HPyV6, HPyV7, TSPyV, HPyV9, HPyV10 (MWPyV), STLPyV, HPyV12 and NJPyV), were based on GenBank sequences (Table [1](#Tab1){ref-type="table"}). The primers and probes for the first 10 except MCPyV were the same as published by Gustafsson et al. \[[@CR53]\] while the primers and probes for STLPyV, HPyV12 and NJPyV were designed for the present study. Primers for MCPyV were reselected due to dimerization of the published primers with primers for STLPyV. The primers were designed in current study by using the Amplify 3X software, version 3.1.4 (Bill Engels, University of Wisconsin) and assessed using an online NCBI Blast analysis. The 5′ ends of the reverse primers of the viral protein 1 (VP1) region were labeled with biotin (5′ biotinylation). The probes were 5′ amine-C12-modified (5′ Aminolink C12).Table 1Sequences of primers and probes, amplicon sizes, amplicon positions (in VP1 region) in target genome and reference strain used in the 13-plex Luminex assay \[[@CR59]\]VirusForward/Reverse (5′ biotinylated) Primers sequence (5′-3′)\
Probe (5′ amine-C12) sequence (5′-3′)Amplicon length (bp)Amplicon position (bp) in target genomeReference strain (GenBank accession no.)JCPyVAATGAGGATCTAACCTGTGGAA/CTGCACCATTGTCATGAGTTGCTTG\
ATGAATGTGCACTCTAATGG1271742--1868J02226BKPyVACAGAGGTTATTGGAATAACTAG/ACTCCCTGCATTTCCAAGGG\
CTTAACCTTCATGCAGGGTC1431952--2094DQ305492KIPyVTTGGATGAAAATGGCATTGG/TAACCCTTCTTTGTCTAAAATGTAGCC\
CTTGGAACAGCTAATAGTAGAATC1422263--2404EF127906WUPyVTTGGATGAAAATGGCATTGG/TAACCCTTCTTTGTCTAAAATGTAGCC\
GAGTACATACAGGGCTTTCCAG1422411--2552EF444554MCPyVTTCCATCTTTATCTAATTTTGCTT/AGGCCTAGTTTTAGATTACCAGAC\
GTAATAGGCCCACCATTTGT1443757--3900EU375803HPyV6TTGCTTCTGGATCCAATACTGC**/**GGCCTCAGGAATTTCAGGCAA\
TGGATGCTGGTTCATCTCTG1311426--1556HM011558HPyV7AAGCAGCTACAACTGGGAACTT/GGCCTCAGGAATTTCAGGCAA\
GCCTACCTTATCCTATGAGTG1251450--1574HM011566TSPyVAGAATGTATGATGACAAAGGTAT/TCTGTAGTTTCCAGTTAGAAAC\
TGAGGGAATGAATTTCCATATGTT1111722--1832GU989205HPyV9ATCTATGGCTCATCCTCAGG/GTAGAGCTAGCAACTAGGCCT\
AGTGCAGGGTACCACTCTC1071862--1968KC831440HPyV10GTCCAGTTCCTACTAAAGTTCCT/TACATCATTGCCCATCCTTGGTT\
GCCGGACACCACAATGACA1061501--1628JQ898292STPyVTGAATATGATCCGTGCCAAA/ACTGCATCAGGGCCTACTTG\
CCTCCTCCAACATGTGTTCC1291318--1446JX463184HPyV12GTAATGGCACCCAAGAGGAA/GGGGATTTAGAAAGGCCTCA\
CCCAGCAGTGTCCCTAAATT1571402--1558JX308829NJPyVTGTGTGCCAAAGAAGTGTCCT/TCTGTCACCTGTTGGAGCATT\
CTGATGCTACTACTGAAATTGAA1591113--1271KF954417Sequences for primers and probes for all except MCPyV, STPyV, HPyV12 and NJPyV as in Gustafsson et al \[[@CR53]\].

Plasmid clones {#Sec6}
--------------

For use as positive controls and to determine assay sensitivities by limiting dilution analysis, plasmids containing each HPyV genome were used. Plasmid DNA was purified using the High Pure Plasmid Isolation Kit (Roche Diagnostics). The concentration of the purified plasmid DNA was determined with the NanoDrop 2000 (Invitrogen, Carlsbad, CA, USA) and the corresponding genome copies were calculated based on the concentration and molecular weight of the plasmid. A 10-fold dilution series of 10^8^ to 10^0^ copies/μL of HPyV DNA was prepared for each of the 13 HPyVs in PCR-grade H~2~O, aliquoted, and stored at −20 °C.

Multiplex PCR for HPyV detection using the Luminex platform {#Sec7}
-----------------------------------------------------------

All the HPyV assays were at first performed in singleplex format and then multiplexed. After confirming that each individual primer pair amplified specifically its plasmid sequence, the primer pairs were combined. The multiplex nucleic acid amplification was conducted as below. In brief, 5 μL DNA templates were mixed in a 20 μL multiplex reaction consisting of 12.5 μL of 2× multiplex PCR mastermix (Qiagen), 0.2 μM of each forward primer and 1 μM of each biotinylated reverse primer. The amplification conditions were 95 °C for 15 min, 40 cycles at 94 °C for 20 s, 50 °C for 90 s, 71 °C for 1 min and 20 s, and a final extension at 71 °C for 10 min.

HPyV singleplex nested PCR {#Sec8}
--------------------------

Each positive specimen was amplified and confirmed with the corresponding HPyV singleplex nested PCR (JCPyV, WUPyV, MCPyV, HPyV, and TSPyV). PCR-grade H~2~O was included in each experiment. In brief, 3 μL of amplified DNA template was mixed in a 22 μL multiplex reaction consisting of 12.5 μL of 2× multiplex PCR mastermix (Qiagen), 0.2 μM of the corresponding forward primer and 0.2 μM of the corresponding biotinylated reverse primer. The amplification conditions were the same as with the multiplex PCR.

Luminex-based suspension array procedure (oligonucleotide coupling, hybridization, and measurement) {#Sec9}
---------------------------------------------------------------------------------------------------

*Oligonucleotide coupling;* thirteen capture probes were included in the multiplex assay (Table [1](#Tab1){ref-type="table"}). Each probe sequence represented the reverse complement to the target region of the biotinylated PCR product. Different sets of carboxylated fluorescent microbeads were obtained from Luminex Corp. ('s-Hertogenbosch, The Netherlands), and oligonucleotide probes for target viruses were assigned to individual bead sets. The oligonucleotide coupling was done according to the manufacturer's instructions (xMAP cookbook, Luminex). The probe-coupled beads were counted using a hemocytometer and were stored in the dark at +4 °C. *Hybridization;* probe-beads and PCR products were hybridized as published \[[@CR53]\] except that the streptavidin-phycoerythrin (SAPE, Invitrogen) incubation temperature was 48 °C. After three washes the amplicons were labeled with 4 μg/mL SAPE conjugate in 2 M tetramethylammonium chloride (Sigma), 75 mM Tris, 6 mM EDTA and 1.5 g7 L sarkosyl (Sigma), pH 8.0; for 20 min in the dark. *Measurement*; after three washes, the beads and the SAPE signal were analyzed in a Bio-Plex 200 (Bio-Rad).

Data analysis and cutoff definition {#Sec10}
-----------------------------------

The results were measured and calculated by the software Xponent 2.1. The data were expressed as Median Fluorescence Intensity (MFI) of 100 microspheres of each bead type. The cut-off value for a positive result was defined as net MFI two times background mean plus 15 MFI.

Specificity of HPyV multiplex assay {#Sec11}
-----------------------------------

To evaluate the specificity of the multiplex assay, plasmids of each HPyV alone (at 10^5^ copies/μL) and combined were used as template to hybridize with a mixture of 13 type-specific probe-bead sets. Specificity of the multiplex platform was also investigated with virus-free SF9 and HEK 293 cells.

Detection limits of HPyV multiplex assay {#Sec12}
----------------------------------------

To determine the sensitivity of the single and multiplex assays, we tested each virus with 10-fold serial dilutions of the DNA standards. The detection limit was defined as the dilution containing the fewest copies of viral genome (in duplicate testing) that still gave a positive result.

Reproducibility of HPyV multiplex assay {#Sec13}
---------------------------------------

To test the multiplex assay reproducibility, a mixture of all 13 HPyV plasmids (at 10^3^ copies/μL/each HPyV) was analyzed with a mixture of 13 type-specific probe-bead sets. Intra-assay variation was calculated with triplicates in the same run, and inter-assay variation in 3 distinct runs.

Results {#Sec14}
=======

We designed a multiplex assay for the detection and identification of 13 HPyVs, by extension of a previously designed multiplex assay for 10 HPyVs \[[@CR53]\]. The assay conditions in this study were optimized for the following parameters: amounts of HPyV-specific probes, each coupled to a distinct Luminex bead, amounts of forward primer and biotinylated reverse primer; hybridization conditions; SAPE concentration; incubation time for SAPE staining; and numbers of washing cycles (data not shown).

Specificity of HPyV multiplex assay {#Sec15}
-----------------------------------

PCR-grade H~2~O was included in each experiment to determine background. Specificity of the assay was assessed with plasmids containing the respective HPyV VP1 inserts. Plasmids of each of the 13 HPyVs alone and combined (10^5^ copies/μl/each HPyV) were used as template for singleplex/multiplex amplification and hybridization. The multiplex assay did identify correctly all the 13 target sequences, with no cross reactions (Table [2](#Tab2){ref-type="table"}). Furthermore, we tested the specificity of the multiplex assay with virus-free SF9 and HEK 293 cells, with no positive signals obtained (data not shown).Table 2Specificities of 13 type-specific probes employed in multiplex HPyV genotypingTarget sequenceHPyV type-specific probe (MFI)BKPyVJCPyVKIPyVWUPyVMCPyVHPyV6HPyV7TSPyVHPyV9HPyV10HPyV11HPyV12HPyV13BKPyV2105433536335442273434443519JCPyV3911453232323434243928473220KIPyV4948252245424343384844594717WUPyV3336295704313165183526432919MCPyV4646373827364541314037493921HPyV63838343233319635303431443523HPyV74346385235422574294141513718TSPyV5252457442466428944742584719HPyV95048444047473929138839544918HPyV103836333234363221335116473124HPyV114756425145666157595817826617HPyV12555042484550463846396168120HPyV133942363637394027403548372327Mix HPyVs74513671518288415111586112573360326396123261631cutoff8581778177837775817210773127Each line represents a single well with each HPyV plasmid (10^5^ copies/μL) or plasmid mix hybridized to a mixture of 13 distinct beads

Limit of detection of HPyV multiplex assay {#Sec16}
------------------------------------------

To determine the sensitivities of the single- and multiplex assays, each HPyV plasmid was diluted serially from 10^8^ to 10^0^ in PCR-grade H~2~O. The limit of detection was the dilution containing the fewest copies in duplicate of viral genome that still gave a positive result. The analytical sensitivities in singleplex and multiplex format ranged from 10^0^ to 10^2^ copies per microliter with all 13 HPyVs (Table [3](#Tab3){ref-type="table"}).Table 3Limits of detection of 13 HPyVs in singleplex and multiplex formatHPyVLimits of detection per μL of DNA extractSingleplexMultiplexBKPyV10^1^10^1^JCPyV10^1^10^1^KIPyV10^1^10^1^WUPyV10^1^10^1^MCPyV10^1^10^2^HPyV610^1^10^1^HPyV710^2^10^2^TSPyV10^1^10^1^HPyV910^1^10^2^HPyV1010^0^10^1^HPyV1110^1^10^2^HPyV1210^0^10^1^HPyV1310^1^10^1^

Intra-assay and inter-assay reproducibility of HPyV multiplex assay {#Sec17}
-------------------------------------------------------------------

The reproducibility of HPyV multiplex assay was determined with a mixture of all 13 HPyV plasmids (10^3^ copies/μL/each HPyV) and a mixture of 13 type-specific probe-bead sets. The coefficient of variation obtained from triplicates in a single run ranged from 2.9% to 9.2% and from three independent runs ranged from 5.7% to 18.8%.

Application of HPyV multiplex assay on tissues {#Sec18}
----------------------------------------------

The multiplex assay was applied to tonsillar samples obtained from children and adults. Among the 78 tissue donors the assay tested positive as follows: BKPyV (*n* = 0), JCPyV (*n* = 1), KIPyV (*n* = 0), WUPyV (*n* = 3), MCPyV (*n* = 1), HPyV6 (*n* = 6), HPyV7 (*n* = 0), TSPyV (*n* = 3), HPyV9 (*n* = 0), and HPyV10 (*n* = 0), STLPyV (*n* = 0), HPyV12 (*n* = 0), and NJPyV (*n* = 0). Co-infection of WUPyV and TSPyV was observed in one tissue. Altogether 13 specimens tested positive: JCPyV DNA was found in a female (22 year old) with tonsillitis and peritonsillar abscess; MCPyV DNA in a female (46 y) with tonsillitis; and HPyV6 DNA in 4 males and 2 females (33 y median age \[range, 14 to 69\]) with diverse tonsillar conditions. WUPyV DNA occurred in two children (male, aged \<5 years; one with snoring and the other with hypertrophy). TSPyV DNA was detected in a 2-y child (male) with hypertrophy and an 11-y child (male) with no clinical data available. Co-infection with WUPyV and TSPyV was seen in a 6-y child (female) with hypertrophy. Each positive specimen was confirmed with the corresponding PyV singleplex nested PCR(s). No product was generated from the negative control.

Discussion {#Sec19}
==========

The number of HPyVs known has multiplied explosively during the past decade. Infections by these viruses appear ubiquitous since birth. Their DNAs have been found widely in the human body, including lymphoid organs, albeit in low copy numbers \[[@CR54]--[@CR60]\]. Whereas JCPyV, BKPyV, MCPyV and TSPyV are known to be associated with diseases, the others are orphan as regards clinical manifestations.

The currently existing PCR assays are of limited value in multi-HPyV assessment. To this end, sensitive detection methods covering all the HPyVs are needed. By extension and optimization of an earlier one \[[@CR53]\], we here describe the development and validation of a Luminex-based multiplex assay that allows for simultaneous detection of 13 HPyVs. The new assay exhibited a high analytical sensitivity, i.e., ability to detect all HPyVs with detection limits of 10^0^--10^2^ copies per microliter, and suitability for high-throughput analysis. We consider the method advantageous also for analyzing multiple infections. This was demonstrated by the detection of up to 13 types in mixes of HPyV plasmids, and of 2 HPyVs in a single tonsillar sample.

In a previous study \[[@CR61]\] addressing the detection of members of *Polyomaviride* in tonsillar tissues from Chinese children with chronic tonsillar disease, WUPyV, MCPyV, TSPyV, KIPyV, MWPyV, and STLPyV were detected in eleven (11%), four (4.0%), three (3.0%), two (2.0%), two (2.0%), and two (2.0%) of 99 samples, respectively. A single HPyV infection was found in 24 (24%) of the samples, and dual HPyV infections (WUPyV and MCPyV) in 2 (2%) samples. In our previous study, we investigated 229 matched pairs of tonsillar tissue biopsies and corresponding serum samples for the presence of TSPyV and found this emerging HPyV in 8 (3.5%) tonsils, and in none of the sera \[[@CR37]\]. Each of the 8 PCR-positive subjects had antiviral IgG of high avidity but not IgM, disclosing persistence. In the present study, we detected JCPyV, WUPyV, MCPyV, HPyV6, and TSPyV DNA altogether in 14 (18%) of 78 tonsils, and co-infection of two HPyVs (WUPyV and TSPyV) in one tissue. All of these data provide evidence of tonsils serving as shedding site in HPyV reactivation and thus contributing to HPyV transmission.

Note added in submission {#Sec20}
------------------------

After completion of our work, Herberhold et al. (Med Microbiol Immunol, DOI 10.1007/s00430%E2%80%93016%E2%80%930486-6) published tonsillar HPyV DNA prevalence data highly similar to ours by using real-time quantitative PCRs in singleplex format.

Conclusion {#Sec21}
==========

A Luminex-based multiplex assay was developed for epidemiological and diagnostic studies to address whether any of the emerging HPyVs, or infection with HPyV thereof, is associated with disease development. Based on the observed frequent occurrence of HPyVs in human tonsils, we suggest that lymphoid tissue may be a general persistence site for these viruses. Thereby, shedding from this site during reactivation might play a role in HPyV transmission.
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